

Hematopathology, Molecular, and Flow Cytometry Requisition



4142 South Mingo Road, Tulsa, OK. 74146
 (918) 417-6400 Fax (918) 416-0506

PATIENT INFORMATION (Please Provide All Information)

LAST NAME (Please Print Legibly)	FIRST	MIDDLE	PATIENT MRN.	SEX M <input type="checkbox"/> F <input type="checkbox"/>	DATE OF BIRTH [MM / DD / YYYY]
ORDERING PROVIDER			DOCTOR PHONE NUMBER	CLIENT NAME/NUMBER	
ORDERING PROVIDER SIGNATURE					

X: _____

COLLECTION DATE:	Specimen Information	<input type="checkbox"/> Bone marrow and blood	<input type="checkbox"/> Body fluid: Type _____	<input type="checkbox"/> Case No: _____
TIME: <input type="checkbox"/> A.M. <input type="checkbox"/> P.M.		<input type="checkbox"/> Peripheral blood	<input type="checkbox"/> Tissue: Type _____	<input type="checkbox"/> Prior Case No: _____

Note: Ordered tests may not be performed if appropriate diagnostic or pathologic codes are not submitted. Most cytogenetic, flow cytometry, FISH and molecular tests require pre-authorization obtained by ordering clinician for coverage. If there is no pre-authorization, an ABN form may be required to perform testing.

Clinical Findings or History ICD10 codes (must have appropriate codes for testing): _____

Working diagnoses/concerns _____

Evaluation requested

- Complete Bone marrow and peripheral blood evaluation (including flow cytometry, cytogenetics, FISH and molecular studies if indicated per pathologist findings and clinical concern)
- Hemepath Consult (CBC and Pathologist report of findings)
- HemePath Consult with Client Submitted CBC
- Tissue or fluid morphologic assessment: Type _____

- Microbiology Cultures -
- Anaerobic Aerobic Fungus AFB
- (Note: Molecular testing recommended for viral infection evaluation, not viral cultures)

Flow Cytometry

- Screening panel (blasts, lymphocytes, myeloid cells (expand if needed)
- T and B cell disorder/lymphoma panel (expand if needed)
- Plasma cell neoplasm/myeloma
- Acute leukemia panel
- PNH Panel

Cytogenetic/molecular testing

- Chromosomal karyotype analysis (blood, bone marrow)
- Myeloid Neoplasms/myeloproliferative/AML**
- NGS Panel, myeloid disorders
- FISH: PML/RARA, t(15;17) for Acute Promyelocytic Leukemia
- FISH: 11q23 (MLL/KMT2A) Rearrangement
- FISH: AML1/ETO, t(8,21)
- FISH: CFBF, Inv(16), t(16;16)
- FISH: BCR/ABL t(9;22)
- FISH: Myeloid Disorder Panel (chromosomes 5, 7, 8, 20)
- PCR: PML/RARA t(15;17), Quantitative
- PCR: CEBPA Mutation
- PCR: FLT3 Mutations (ITD)
- PCR:RUNX1 Mutation
- PCR:KIT Mutation
- PCR: NPM1 (Exon 12) Mutation
- PCR: IDH1/IDH2 Mutation
- PCR:TP53 Mutation
- PCR: JAK2 V617F Mutation
- MPN Molecular Panel including JAK2 exon 12, MPL, CALR (only performed if negative for JAK2 V617F)
- FISH: CHIC2 deletion (FIP1L1-PDGFRFA) 4q12 PDGFRB and FLP1 (rearrangements will be detected by chromosomal karyotypic analysis)

Acute lymphoblastic leukemia/ALL/Lymphoma/LPDs/Plasma cell neoplasms

- FISH: BCR/ABL, t(9;22)
- FISH: BCR/ABL with reflex testing for BCR-ABL-like
- FISH: 11q23 (MLL/KMT2A) Rearrangement
- FISH: t(12;21) ETV/RUNX1
- PCR: BCR/ABL t(9;22), quantitative
- Lymphoma, LPDs, and Plasma cell neoplasm**
- Multiple Myeloma FISH Panel: t(4;14) FGFR2/IGH fusion; t(11;14)CCND1/IGH fusion; t(14;16)IGH/MAF fusion; TP53/17 cep loci:CKS1B/CDKN2C loci
- FISH for multiple myeloma panel, MGUS, PCD
- FISH: B-Cell CLL Panel [+12, del13q14.3, del 13q34, del17p13.1, del11q22.3]
- FISH: Mantle Cell Lymphoma CCND1/IGH t(11;14)
- FISH: Follicular Lymphoma IGH/BCL2 t(14;18)
- FISH: Burkitt Lymphoma, MYC/IGH t(8;14)
- FISH: MYC, 8q24 Rearrangement
- FISH: MYC w/ reflex to BCL2 (18q21), and BCL6 (3q27)
- PCR: Mantle Cell Lymphoma, CCND1/IGH t(11;14)
- PCR: B-Cell (IgH, Heavy Chain) Gene Rearrangement
- PCR: T-Cell Receptor (TCR) Gene Rearrangement

Solid Tumor, Molecular Testing

- Lung Panel NGS
- Melanoma Panel NGS
- Solid Tumor Panel NGS
- Colon Panel NGS
- PDL-1 (22C3 IHC with Tumor Proportion Score (TPS) Keytruda
- PDL-1 (22C3 IHC with Combined Positive Score (CPS) Keytruda
- PDL-1 (28-8 pharmDX by IHC w/interp Opdivo)
- PDL-1 (SP263 IHC with Tumor Proportion Score (TPS) Tecentriq and cemiplimab-rwlc Libtayo
- MMR by IHC